New York State Common Retirement Fund Purchases 6,564 Shares of Evolent Health, Inc. (NYSE:EVH)

New York State Common Retirement Fund boosted its position in shares of Evolent Health, Inc. (NYSE:EVH) by 6.9% in the fourth quarter, Holdings Channel reports. The firm owned 101,472 shares of the technology company’s stock after purchasing an additional 6,564 shares during the period. New York State Common Retirement Fund’s holdings in Evolent Health were worth $3,352,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Evolent Health in the 3rd quarter valued at $74,520,000. Wellington Management Group LLP increased its holdings in shares of Evolent Health by 11.9% in the third quarter. Wellington Management Group LLP now owns 4,239,198 shares of the technology company’s stock worth $115,433,000 after acquiring an additional 449,664 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Evolent Health by 2.7% during the third quarter. Vanguard Group Inc. now owns 10,594,640 shares of the technology company’s stock worth $288,492,000 after purchasing an additional 274,288 shares during the period. Redmile Group LLC lifted its holdings in shares of Evolent Health by 118.0% during the 3rd quarter. Redmile Group LLC now owns 465,282 shares of the technology company’s stock valued at $12,670,000 after purchasing an additional 251,850 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Evolent Health by 8.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,655,609 shares of the technology company’s stock valued at $45,082,000 after purchasing an additional 133,038 shares during the period.

Analyst Ratings Changes

EVH has been the topic of a number of research reports. Canaccord Genuity Group cut their price target on shares of Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, March 28th. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th. Oppenheimer began coverage on Evolent Health in a research note on Friday, March 1st. They issued an “outperform” rating and a $45.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. Finally, JMP Securities lifted their target price on Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.70.

Evolent Health Price Performance

Shares of EVH opened at $27.10 on Monday. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -21.34 and a beta of 1.57. The company’s fifty day simple moving average is $31.41 and its 200 day simple moving average is $30.28. Evolent Health, Inc. has a 1-year low of $23.33 and a 1-year high of $35.83. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The business had revenue of $556.06 million for the quarter, compared to analysts’ expectations of $541.87 million. On average, research analysts forecast that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.